Cases & Deals

Celgene asserts its REVLIMID® patents against Apotex Inc. under Hatch-Waxman Act

Client(s) Celgene Corporation

Jones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Apotex Inc. in a Hatch-Waxman litigation matter involving Apotex’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.

Celgene Corporation v. Apotex Inc., No. 2-18-cv-00461 (D.N.J.)